Efficacy of Sub-Conjunctival Injection of Mitomycin C Versus Bevacizumab in Pterygium Treatment: Pakistani Population
DOI:
https://doi.org/10.36283/ziun-pjmd14-1/009Keywords:
Pterygium, Mitomycin C, BevacizumabAbstract
Background: Pterygium is a progressive fibrovascular tissue that affects the conjunctiva and cornea. The aim of the study was to compare the efficacy of Sub-conjunctival injection of Mitomycin C versus Bevacizumab in pterygium treatment focusing on their impact on recurrence rates to improve postoperative outcomes.
Methods: The Randomized clinical trial was conducted in the Ophthalmology department of Ziauddin University over 8 months. 54 patients aged above 18 with grade 2 or 3 pterygium were divided into 2 groups of 27. Group A received a Subconjunctival injection of Mitomycin C while Group B received Bevacizumab. Patients were monitored at 1st and 3rd week post injection followed by pterygium excision 1 month later. The postoperative follow-up was conducted at the 1st, 3rd, and 6th months to assess improvement in symptoms and recurrence. The data was analyzed using SPSS version 23; the Chi-square test and Paired T-test were applied with a significance level of p < 0.05.
Results: The study analyzed data from 54 patients with pterygium, having a mean age of 42.03±8.23 years, with a male-to-female ratio of 3:1. The common symptoms were Redness (40.74%), itching (27.8%), and decreased visual acuity (31.4%). Post-injection outcome in terms of pterygium vascularity and thickness was better in group B. The recurrence rates at the 6th-month post excision were 1 (7.4%) and 3 (18.5%) in group B.
Conclusion: Mitomycin C as an adjuvant treatment demonstrates superior efficacy in reducing pterygium recurrence and improving postoperative vision, compared to Bevacizumab.
References
Yoon CH, Seol BR, Choi HJ. Effect of pterygium on corneal astigmatism, irregularity, and higher-order aberrations: A comparative study with normal fellow eyes. Scientific Reports. 2023 May; 13(1). https://doi.org/10.1038/s41598-023-34466-4.
Palewski M, Budnik A, Konopińska J. Evaluating the efficacy and safety of different pterygium surgeries: A review of the literature. International Journal of Environmental Research and Public Health. 2022 Sept; 19(18). https://doi.org/10.3390/ijerph191811357.
Shahraki T, Arabi A, Feizi S. Pterygium: An update on pathophysiology, clinical features, and Management. Therapeutic Advances in Ophthalmology. 2021 Jan; 13. DOI: 10.1177/25158414211020152.
Sakti FK. Updates on the mechanism and management of Pterygium: A Brief Review. European Journal of Medical and Health Sciences. 2021 Jul; 3(4):6–11. doi:10.24018/ejmed.2021.3.4.949.
Alsarhani W, Alshahrani S, Showail M, Alhabdan N, Alsumari O, Almalki A, et al. Characteristics and recurrence of pterygium in Saudi Arabia: A single-center study with a long follow‐up. BMC Ophthalmology. 2021 May; 21(1). DOI: 10.1186/s12886-021-01960-0
Shoaib KK. Conjunctival autograft with Mitomycin C (MMC) in primary pterygium excision. Pakistan Journal of Ophthalmology. 2023 Sept; 39(4). doi:10.36351/pjo.v39i4.1731
Akbari M .Update on overview of pterygium and its surgical management. Journal of Population Therapeutics and Clinical Pharmacology. 2022 Jan; 29(4):30-45. https://doi.org/10.47750/jptcp.2022.968
Chu WK, Choi HL, Bhat AK, Jhanji V. Pterygium: New insights. Eye. 2020 Feb; 34(6):1047–50. doi:10.1038/s41433-020-0786-3
Gulani AC, Gulani AA.
Cosmetic pterygium surgery: Techniques and long-term outcomes. Clinical Ophthalmology. 2020 Jun; 14:1681–7. https://doi.org/10.2147/OPTH.S251555
Al-Salem KM, Saif ATS, Saif PS. Comparing adjuvant beta radiation, mitomycin C, and conjunctival autograft in primary pterygium treatment, a three-year follow-up study. The Open Ophthalmology Journal. 2021 Jan; 14(1):82–7. http://dx.doi.org/10.2174/1874364102014010082.
Tawfiq Awad M, Mohamed Saleh M, Elsayed Ibrahim Y, Kotb A. Outcome of surgical management of pterygium: Review article. Zigzag University Medical Journal. 2024 Sep; 30(1.6): 2732-2738. DOI: 10.21608/zumj.2023.254241.3039.
Mohammadi SO, Sargazi M, Ahmadi SS, Bagherzadeh O, Arish M. Effect of intralesional injection of interferon alpha-2b on pterygium treatment. Investigative Ophthalmology and Visual Science. 2023; 64(8).
Yu J, Feng J, Jin T, Tian L, Zhu L, Cao K, et al. The Effect of a Novel Strategy in Treating Primary Pterygium: A Prospective Randomized Clinical Study. American Journal of Ophthalmology. 2021 May; 225:108–16. .DOI: 10.1016/j.ajo.2021.01.001
Alfarhan A, Alhamzah A, Abuabat A, Debasi T, Almudhaiyan T. Surgical Preferences in the Management of Primary Pterygium among Anterior Segment Specialists. The Open Ophthalmology Journal. 2021 Dec; 15(1):322–8.. DOI: 10.2174/1874364102115010322.
Gupta V, Gupta P. Preoperative subconjunctival injection of mitomycin C as an adjunctive treatment 24 hours before excision of primary pterygium. Middle East African Journal of Ophthalmology. 2012; 19(4):437-8. doi:10.4103/0974-9233.102774.
Ghiasian L, Samavat B, Hadi Y, Arbab M, Abolfathzadeh N. Recurrent pterygium: a review. Journal of Current Ophthalmology. 2021; 33(4):367–78. doi:10.1080/2331205X.2020.1724602
Denis E, Pauline A, Charity Z, Pius M, Jacob N, Agaba CA. Pterygium in Uganda: A hospital-based study. Schumacher U, editor. Cogent Medicine. 2020 Feb; 7(1). doi:10.1080/2331205X.2020.1724602.
Khan B, Sohail A, Faridi TA, Jan U, Zahid F, Parveen I. Relation between different grades of pterygium and amount of induced corneal astigmatism. Pakistan Biomed J. 2021; 4(2):59–63. https://doi.org/10.54393/pbmj.v4i2.
Abraham PA, Brooks G, Dadas C, Hovanesian J, Lee J, Ni J, Whitcup S. Prevalence of pterygium in the United States: a claims-based analysis. Invest. Ophthalmol. Vis. Sci. 2023; 64(8).
Zhang B, Dong X, Sun Y. Efficacy and safety of anti-vascular endothelial growth factor agents in the treatment of primary pterygium. Frontiers in Medicine. 2023; 10. https://doi.org/10.3389/fmed.2023.1166957.
Mahmoud MA, Shams HE, Amer Y, Amin AK. Evaluation of adjunctive subconjunctival injection of bevacizumab before pterygium surgery. Egypt Journal of Hospital Medicine. 2024; 94(1): 343-351. https://api.semanticscholar.org/CorpusID:267303495.
Sayadi J, Gouider D, Henchiri M, Choura R, Boujelbene N, Abbes I, et al. Preoperative intralesional bevacizumab injection in primary pterygium in Tunisian patients: a randomized controlled prospective study. Journal of Current Ophthalmology. 2022; 34(3) :297–304. DOI: 10.4103/joco.joco_146_22
Hassan HT. The role of mitomycin-C (MMC) in primary pterygium surgery for prevention of recurrence. Clinical Ophthalmologist Journal. 2020; 1(1):019-28.
Parveen S, Naeem S, Muzaffar W, Saeed MK, Babar Z. Sub-conjunctival injection of 5 fluorouracil versus bevacizumab in the treatment of primary pterygium. Pakistan Journal of Ophthalmology. 2023 Sep; 39(4). https://doi.org/10.36351/pjo.v39i4.1651.
Agahan ALD, Merca TGB, Tecson III JV, Panganiban MA. Recurrence and Complication Rates among Current Pterygium Treatment Techniques: Pre-operative Subpterygeal Mitomycin-C Injection, Intraoperative Mitomycin C Application and Pterygium Excision with Conjunctival Autograft. Acta Medica Philippina. 2020 Oct 28;54(5).DOI: https://doi.org/10.47895/amp.v54i5.2242
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
Metrics
How to Cite
